



Ziopharm Oncology to Announce Third Quarter 2018 Financial Results, Host Conference Call Nov. 8

October 31, 2018

BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](http://www.ziopharm.com), Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, Nov. 8, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended Sept. 30, 2018.

The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 7763857. To access the slides and live webcast or the subsequent archived recording, visit the "Investors & Media" section of the Ziopharm website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two weeks.

About Ziopharm Oncology, Inc.

Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective, and scalable immunotherapies for the treatment of multiple cancer types: Controlled IL-12 and *Sleeping Beauty* for genetically modifying T cells. The Company's lead asset, Ad-RTS-hIL-12 plus veledimex, has demonstrated in clinical trials the potential to control interleukin-12, leading to an infiltration of T cells that fight solid tumors. Ad-RTS-hIL-12 plus veledimex is being evaluated as a monotherapy and in combination with an immune checkpoint inhibitor to treat brain cancer. The Company also is advancing therapies using *Sleeping Beauty*, a non-viral approach to genetically modifying T cells to express chimeric antigen receptors (CAR) and T-cell receptors (TCR), which target specific antigens in blood cancers and neoantigens such as in solid tumors. *Sleeping Beauty* is currently in a clinical trial to generate CD19-specific CAR⁺ T cells and to support the Company's so-called "point-of-care" technology, a very-short T-cell manufacturing process which potentially can be developed as a decentralized manufacturing process based in hospitals. These platforms are being advanced in collaboration with MD Anderson Cancer Center and the National Cancer Institute.

Forward-Looking Statements Disclaimer

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include but are not limited to: the Company's ability to advance certain activities; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of other product candidates will advance further in the preclinical research or clinical trial process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the Company's other therapeutic products it develops will be successfully marketed if approved; the strength and enforceability of the Company's intellectual property rights; competition from other pharmaceutical and biotechnology companies; as well as other risk factors contained in the Company's periodic and interim reports filed from time to time with the Securities and Exchange Commission, including but not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and subsequent reports that the Company may file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Company contacts:

David Connolly

Vice President, Corporate Communications and Investor Relations

617-502-1881

dconnolly@ziopharm.com

Mike Moyer

Vice President, Portfolio Strategy

617-765-3770

mmoyer@ziopharm.com



